Volume 22, Number 3—March 2016
Research
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
Table 3
Exposure | Stratifier | Multivariable regression, time ratio (95% CI) | p value |
---|---|---|---|
Xpert MTB/RIF | Previous TB | ||
Not conducted | No | Baseline | |
Conducted, rifampin-resistant TB | No | 0.16 (0.12−0.21) | <0.001 |
Not conducted | Yes | Baseline | |
Conducted, rifampin-resistant TB |
Yes |
0.34 (0.21–0.55) |
<0.001 |
Previous TB | Xpert MTB/RIF | ||
No | Not conducted | Baseline | |
Yes | Not conducted | 0.80 (0.62–1.04) | 0.09 |
No | Conducted, rifampin-resistant TB | Baseline | |
Yes | Conducted, rifampin-resistant TB | 1.69 (1.03–2.76) | 0.04 |
*Association between use of Xpert MTB/RIF and time to MDR TB treatment initiation was stratified by the effect modifier previous tuberculosis. Association between previous tuberculosis and time to MDR TB treatment initiation was stratified by Xpert use. There were 372 patients in the model. All results derived from the final model shown in Table 2. Median in baseline strata of Xpert MTB/RIF and previous tuberculosis was 41 days. MTB, Mycobacterium tuberculosis; RIF, rifampin. MDR TB, multidrug-resistant tuberculosis; NA, not applicable.
1These authors contributed equally to this article.
Page created: March 01, 2016
Page updated: March 01, 2016
Page reviewed: March 01, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.